The Exon 20 Group is a multi-stakeholder global organization of pan-tumor EGFR exon 20 insertion and HER2 exon 20 insertion patients, care partners, thoracic/medical oncologists, scientists, molecular pathologists, comprehensive biomarker testing labs, and pharma and biotech leadership, all working to turn exon 20 insertion-driven cancers into chronic and manageable diseases and then cure them. The Exon 20 Group offers free services including direct patient navigation, oncology nursing services, social media groups on Facebook and Inspire, molecular profiling lab connections, clinical trials matching, expanded access matching, peer-to-peer counseling, survey research and advisory board opportunities, as well as virtual patient and care partner meetings. The Exon 20 Group's International Research Consortium is working on cutting-edge research collaborations, a Knowledge Bank, and registries.
Inspire: https://www.inspire.com/groups/exon-20
Contact Us:
Email: exon20@exon20group.org
Phone: 602-618-0183
Connect with us:
Adjuvant Chemoradiotherapy Demonstrated Better Outcomes for Patients With Endometrial Cancer
As Rare Disease Day Approaches, I’m Reflecting on My MPN Diagnosis
First Patient Injected With Novel Radiotherapy in Phase 2b Trial for Brain Cancer
FDA Approves Orserdu for Some Patients with Metastatic Breast Cancer